Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Prolongation of the QT interval was rarely observed, but monitoring and appropriate electrolyte replacement is recommended for those patients at risk for QT prolongation GATA-3 and the production of Th2-associated cytokines e. Mature T-cell malignancies comprise a heterogeneous group of diseases with widely variable clinical courses, ranging from indolent, slowly progressing to rapidly progressing disease, leading to death. While the precise mechanism of action is incompletely understood, evidence suggests that ECP has immunomodulatory effects which may augment host anti-tumor immunity.
For example, in a cohort of 28 SS patients, the presence of fewer than 3 copy number alterations was associated with a median overall-survival of 93 months, compared with a median overall-survival of 67 months for those with 3 or more copy number alterations
This study was comprised largely of peripheral T-cell lymphoma patients, most of whom had refractory disease It exists in both aggressive and more indolent forms. In addition, HDAC inhibitors may have important effects on the tumor microenvironment via reactive oxygen species, enhanced antigen presentation and downregulation of immunomodulatory cytokines, like IL Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: Additional therapeutic approaches, including proteasome inhibitionimmunomodulatory strategiesand more targeted approaches warrant further investigation Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: